Related Experiment Video
Updated: Jan 4, 2026

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
Published on: February 6, 2019
[Proton pump inhibitors in paediatrics]
J Carcelén Andrés1, C Barroso Péez, C Fábrega Bosacoma
1Grupo Español de Farmacia Pediátrica, SEFH. jca@grupobbva.net
Insights
Pediatric proton pump inhibitor use is increasing, but clinical trials are limited. Further research is needed for safe and effective administration in children.
Area of Science:
- Pediatric Gastroenterology
- Pharmacology
- Drug Safety
Context:
- Increasing use of proton pump inhibitors (PPIs) in pediatric patients.
- Limited clinical trial data available for pediatric PPI use.
Purpose:
- To analyze published literature on pediatric PPI use over the last seven years.
- To review the efficacy and safety of commonly used PPIs in children.
Summary:
- Omeprazole and lansoprazole have the most published studies, demonstrating good tolerance and efficacy.
- Main indications include H. pylori eradication, GERD, and esophagitis.
- Lack of pediatric-specific formulations and administration challenges noted.
Impact:
- Highlights the need for more robust clinical trials in pediatric populations.
- Emphasizes the necessity of determining age-specific pharmacokinetic parameters for safe and effective PPI use.
- Calls for authorization by health authorities based on comprehensive data.
Abstract:
In last years the use in the pediatric area of proton pump inhibitors (omeprazole, lansoprazole, pantoprazole, rabeprazole and esomeprazole) is more often, nevertheless the clinical trials carried out are poor. The aim of this work is to analyse the bibliography published about this kind of drugs in children and to make a revision of its use in the last seven years. More studies with omeprazole and lansoprazole have been developed, to be exact omeprazole and lansoprazole is present in 122 bibliographic appointments and 34 for lansoprazole, which include studies that demonstrate a good tolerance and efficacy. The remaining proton pump inhibitors count with very few studies. The main therapeutic indications were the eradication of Helicobacter pylori, gastroesophageal reflux disease and esophagitis. The number of patients included in the reviewed studies is quite heterogeneous, from 8 to 122 and the age range between 8 days and 17 years. On the other hand, it could be highlighted the non-existence of formulations adapted to the pediatric population and the difficulty of administration specially in the youngest patients. As in many other drugs, it would be necessary to carry out clinical trials in order to determinate the pharmacologic parameters at difference ages, which will allow a safe and effective administration, and its authorization by all Health Authorities.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Distribution
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Excretion
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

